• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and diagnostic laboratory immunology >Recombinant Human Gamma Interferon in Human Immunodeficiency Virus-Infected Children: Safety, CD4+-Lymphocyte Count, Viral Load, and Neutrophil Function (AIDS Clinical Trials Group Protocol 211)
【24h】

Recombinant Human Gamma Interferon in Human Immunodeficiency Virus-Infected Children: Safety, CD4+-Lymphocyte Count, Viral Load, and Neutrophil Function (AIDS Clinical Trials Group Protocol 211)

机译：感染人类免疫缺陷病毒的儿童中的重组人类γ干扰素：安全性，CD4 +淋巴细胞计数，病毒载量和中性粒细胞功能（艾滋病临床试验小组协议211）

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Nineteen children with human immunodeficiency virus (HIV) infection were treated with recombinant human gamma interferon (rIFN-γ) (50 μg/m2 subcutaneously three times each week during weeks 1 through 12 and 100 μg/m2 subcutaneously three times each week during weeks 13 through 24) in a phase I/II clinical trial. All children continued to receive previously prescribed therapy with oral zidovudine or didanosine. Children were assessed clinically and with laboratory studies during 24 weeks of study treatment and for 12 weeks after completion of rIFN-γ therapy. In general, rIFN-γ therapy was well tolerated. There were two clinical or laboratory adverse events thought to be possibly or probably study drug associated. One child developed acute pancreatitis; another child developed granulocytopenia. Median CD4+-lymphocyte counts and plasma HIV RNA concentrations did not change significantly during therapy. In vitro neutrophil bactericidal activity against Staphylococcus aureus and superoxide production were not significantly affected by rIFN-γ therapy. We conclude that rIFN-γ therapy in HIV-infected children receiving single-agent antiretroviral therapy is safe and does not produce consistent changes in CD4+-lymphocyte count, plasma HIV RNA concentration, or in vitro neutrophil function.
机译：在第1周至第12周内，每周三次皮下注射重组人γ干扰素（rIFN-γ）（50μg/ m 2 ）治疗19例人类免疫缺陷病毒（HIV）患儿，每周1至12周，每次100μg/ m在I / II期临床试验中，每周13至24周内每周三次皮下 2 。所有儿童继续接受口服齐多夫定或去羟肌苷的处方治疗。在研究治疗的24周内和完成rIFN-γ治疗后的12周内对儿童进行临床评估和实验室研究。通常，rIFN-γ疗法耐受性良好。有两个临床或实验室不良事件被认为可能或可能与药物相关。 1名儿童发展为急性胰腺炎。另一个孩子出现粒细胞减少症。治疗期间，CD4 + -淋巴细胞计数中位数和血浆HIV RNA浓度无明显变化。 rIFN-γ治疗对中性粒细胞对金黄色葡萄球菌的杀菌活性和超氧化物的产生没有显着影响。我们得出结论，在接受单药抗逆转录病毒治疗的HIV感染儿童中，rIFN-γ治疗是安全的，不会在CD4 + 淋巴细胞计数，血浆HIV RNA浓度或体外中性粒细胞功能方面产生一致的变化。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号